DR. KERRY J. RESSLER, MD,PHD
Psychiatric in Atlanta, GA
License number
Georgia 046223
Category
Psychiatric
Type
Psychiatry
Address
Address
954 NE Yerkes Research Ctr, Atlanta, GA 30329
Phone
(404) 778-5526
Personal information
See more information about KERRY J. RESSLER at radaris.comName
Address
Phone
3252 Inman Dr NE, Atlanta, GA 30319
3596 Chelsea Cres NE, Atlanta, GA 30319
Professional information
Professor At Emory University
Position:
Associate Professor at Emory University
Location:
Greater Atlanta Area
Industry:
Research
Work:
Emory University
-
Associate Professor
Education:
Harvard Medical School 1990 - 1997
md Massachusetts Institute of Technology 1986 - 1990
bs
md Massachusetts Institute of Technology 1986 - 1990
bs
Kerry J Ressler, Atlanta GA
Specialties:
Psychiatrist
Address:
954 Gatewood Rd Ne, Atlanta, GA 30329
Board certifications:
American Board of Psychiatry and Neurology Certification in Psychiatry (Psychiatry and Neurology)
Kerry James Ressler, Atlanta GA
Specialties:
Physical Medicine & Rehabilitation, Psychiatry
Work:
The Emory Clinic 'B'
1365 Clifton Rd Ne, Atlanta, GA 30322 Yerkes Research Center Emory School of Medicine
954 Gatewood Rd NE, Atlanta, GA 30329 Grady Meml. Hosp.
80 Jesse Hill Jr Dr SE, Atlanta, GA 30303
1365 Clifton Rd Ne, Atlanta, GA 30322 Yerkes Research Center Emory School of Medicine
954 Gatewood Rd NE, Atlanta, GA 30329 Grady Meml. Hosp.
80 Jesse Hill Jr Dr SE, Atlanta, GA 30303
Education:
Harvard University(1997)
Dr. Kerry J Ressler, Atlanta GA - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
Emory Clinic Psychiatry
1365 Clifton Rd NE SUITE B6100, Atlanta 30322
(404) 778-5526 (Phone)
1365 Clifton Rd NE SUITE B6100, Atlanta 30322
(404) 778-5526 (Phone)
Certifications:
Psychiatry, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Emory Clinic Psychiatry
1365 Clifton Rd NE SUITE B6100, Atlanta 30322
Emory University Hospital
1364 Clifton Rd North #East, Atlanta 30322
1365 Clifton Rd NE SUITE B6100, Atlanta 30322
Emory University Hospital
1364 Clifton Rd North #East, Atlanta 30322
Education:
Medical School
Harvard Medical School
Graduated: 1994
Emory University School Of Med
Harvard Medical School
Graduated: 1994
Emory University School Of Med
Acute Pharmacologic Augmentation Of Psychotherapy With Enhancers Of Learning Or Conditioning
US Patent:
2005009, May 5, 2005
Filed:
Aug 24, 2004
Appl. No.:
10/924591
Inventors:
Michael Davis - Stone Mountain GA, US
Kerry Ressler - Chamblee GA, US
Kerry Ressler - Chamblee GA, US
Assignee:
Emory University - Atlanta GA
International Classification:
A61K031/55, A61K031/137
US Classification:
514649000, 514220000
Abstract:
Methods for treating an individual with a psychiatric order with a pharmacologic agent that enhances learning or conditioning in combination with a session of psychotherapy are provided. These methods of the invention encompass a variety of methods of psychotherapy, including exposure-based psychotherapy, cognitive psychotherapy, and psychodynamically oriented psychotherapy, and psychiatric orders including fear and anxiety disorders, addictive disorders including substance-abuse disorders, and mood disorders. The pharmacologic agents used for the methods of the present invention are ones that generally enhance learning or conditioning, including those that increase the level of norepinephrine in the brain, those that increase the level of acetylcholine in the brain, and those that enhance N-methyl-D-aspartate (NMDA) receptor transmission in the brain.
Acute Pharmacologic Augmentation Of Psychotherapy With Enhancers Of Learning Or Conditioning
US Patent:
2011003, Feb 17, 2011
Filed:
Oct 21, 2010
Appl. No.:
12/909416
Inventors:
Michael Davis - Stone Mountain GA, US
Kerry J. Ressler - Atlanta GA, US
Kerry J. Ressler - Atlanta GA, US
International Classification:
A61K 31/42, A61P 25/00
US Classification:
514380
Abstract:
Methods for treating an individual with a psychiatric disorder with a pharmacologic agent that enhances learning or conditioning in combination with a session of psychotherapy are provided. These methods of the invention encompass a variety of methods of psychotherapy, including exposure-based psychotherapy, cognitive psychotherapy, and psychodynamically oriented psychotherapy, and psychiatric disorders including fear and anxiety disorders, addictive disorders including substance-abuse disorders, and mood disorders. The pharmacologic agents used for the methods of the present invention are ones that generally enhance learning or conditioning, including those that increase the level of acetylcholine in the brain, and those that enhance N-methyl-D-aspartate (NMDA) receptor transmission in the brain.
Augmentation Of Psychotherapy With Cannabinoid Reuptake Inhibitors
US Patent:
2006008, Apr 20, 2006
Filed:
Oct 19, 2005
Appl. No.:
11/253314
Inventors:
Michael Davis - Stone Mountain GA, US
Kerry Ressler - Atlanta GA, US
Jasmeer Chhatwal - Atlanta GA, US
Jason McDevitt - Williamsburg VA, US
Kerry Ressler - Atlanta GA, US
Jasmeer Chhatwal - Atlanta GA, US
Jason McDevitt - Williamsburg VA, US
International Classification:
A61K 31/519, A61K 31/195
US Classification:
514252160, 514262100, 514283000, 514561000
Abstract:
Methods are provided for facilitating psychological extinction of a deleterious, high-anxiety response that is disproportionate to the threat offered by a given stimulus. An afflicted subject is treated with a cannabinoid reuptake inhibitor in conjunction with extinction training. The methods are relevant for treatment of anxiety disorders, including phobic disorders and PTSD, in addition to other afflictions such as chronic pain, insomnia, and erectile dysfunction.
Augmentation Of Extinction Via Administration Of Sub-Antimicrobial Doses Of D-Cycloserine
US Patent:
2006025, Nov 9, 2006
Filed:
Feb 6, 2006
Appl. No.:
11/347937
Inventors:
Michael Davis - Stone Mountain GA, US
Kerry Ressler - Atlanta GA, US
Jason McDevitt - Williamsburg VA, US
Kerry Ressler - Atlanta GA, US
Jason McDevitt - Williamsburg VA, US
International Classification:
A61K 31/498, A61B 19/00
US Classification:
514250000, 128898000
Abstract:
Methods are provided for facilitating psychological extinction of a deleterious, high-anxiety response that is disproportionate to the threat offered by a given stimulus. An afflicted subject is treated with a sub-antimicrobial dose of D-cycloserine in conjunction with extinction training. The methods are relevant for treatment of anxiety disorders, including phobic disorders and PTSD, in addition to other afflictions such as insomnia and erectile dysfunction.
Sublingual Formulations Of D-Cycloserine And Methods Of Using Same
US Patent:
2010011, May 6, 2010
Filed:
Apr 10, 2008
Appl. No.:
12/594371
Inventors:
Jason P. McDevitt - Williamsburg VA, US
Michael Davis - Stone Mountain GA, US
Kerry J. Ressler - Atlanta GA, US
Michael Davis - Stone Mountain GA, US
Kerry J. Ressler - Atlanta GA, US
International Classification:
A61K 31/42, C07D 261/04, A61P 25/00, A61K 31/519, A61K 31/53, A61K 31/4985
US Classification:
514243, 548244, 514380, 51425216, 514250, 5142621
Abstract:
The invention provides methods and compositions for treating anxiety-related disorders in a subject. The methods include sublingually administering D-cycloserine to a subject with the anxiety-related disorder, either alone or in combination with extinction training.
Method For Facilitating Extinction Training Using D-Cycloserine
US Patent:
2010020, Aug 12, 2010
Filed:
Jan 7, 2010
Appl. No.:
12/683862
Inventors:
Jason P. McDevitt - Williamsburg VA, US
Michael Davis - Stone Mountain GA, US
Kerry J. Ressler - Atlanta GA, US
Michael Davis - Stone Mountain GA, US
Kerry J. Ressler - Atlanta GA, US
International Classification:
A61K 31/42, A61P 25/22, A61P 15/00, A61P 25/20
US Classification:
514380
Abstract:
Methods are disclosed for improving treatment of various medical conditions via administration of D-cycloserine to facilitate learning. Specifically, by administering D-cycloserine on a post-training pre-sleep basis, subsequent to extinction training during the day, the methods can improve upon the known ability of D-cycloserine to facilitate extinction learning.